Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 1

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 1
---
% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock. The public offering price of each Pre-Funded Warrant and accompanying Offered Common Warrant will be equal to the price at which one share of Common Stock and accompanying Offered Common Warrant is sold to the public in this offering, minus $0.0001, and the exercise price of each pre-funded warrant will be $0.0001 per share. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

The shares of Common Stock, or Pre-Funded Warrants in lieu thereof, and the accompanying Offered Common Warrants can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance.

At 12:01 a.m. Eastern time on January 8, 2025, we effected a reverse stock split (the “Reverse Stock Split”) pursuant to which each 100 shares of our Common Stock outstanding immediately prior thereto was converted into 1 share of our Common Stock outstanding immediately thereafter. All information has been retroactively adjusted for the Reverse Stock Split.

As of January 8, 2025, there are 4,263,026 shares of Common Stock outstanding on a fully-diluted basis after giving effect to the conversion of all outstanding shares of our Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (each as defined below) and the exercise of all outstanding Warrants (as defined below) and options, of which 3,953,972 shares were held by non-affiliates (without taking into account beneficial ownership or stock exchange limitations). If all of the 5,102,040 shares of Common Stock offered under this prospectus, including the 4,802,140 shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and Offered Common Warrants, were issued and outstanding as of January 8, 2025 (without taking into account beneficial ownership or stock exchange limitations), such shares would represent approximately 54% of the total number of our fully-diluted shares of Common Stock outstanding and approximately 51% of the total number of our fully-diluted shares of Common Stock held by non-affiliates.

You should read this prospectus and any prospectus supplement or amendment carefully before you invest in our securities.

Our Common Stock is listed on Nasdaq under the symbol “C